Insmed Presents Additional Data From Pivotal ASPEN Study Of Brensocatib In Patients With Bronchiectasis At The 7th World Bronchiectasis Conference
Insmed Presents Additional Data From Pivotal ASPEN Study Of Brensocatib In Patients With Bronchiectasis At The 7th World Bronchiectasis Conference
—New Graph Depicting 52-Week FEV1 Data Illustrate Significantly Less Decline in Lung Function for Brensocatib 25 mg Versus Placebo—
新的图表描绘了52周的FEV1数据，说明Brensocatib 25 mg相对于安慰剂引起的肺功能下降明显减少。
—Additional Exploratory Endpoints to be Presented, Including FVC and Patient-Reported BEST Score—
还将呈现其他探索性终点，包括FVC和患者报告的BEST评分。
BRIDGEWATER, N.J., July 3, 2024 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that additional positive results from the ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis, will be presented tomorrow, July 4, 2024, at the 7th World Bronchiectasis Conference (WBC) in Dundee, Scotland. Slides from this presentation can be found here.
新泽西州布里奇沃特，2024年7月3日 /美通社/--全球生物制药公司Insmed Incorporated (纳斯达克:INSMD)于今日宣布，将于明天2024年7月4日在苏格兰邓迪举行的第七届世界支气管扩张症状大会 (WBC)上呈现ASPEN研究的附加正面研究结果。这是一项全球性的随机双盲安慰剂对照3期研究，旨在评估Brensocatib对非囊性纤维化支气管扩张症患者的疗效、安全性和耐受性。此演示文稿的幻灯片可在此处找到。